Equities research analysts expect Lyra Therapeutics, Inc. (NASDAQ:LYRA) to report earnings of ($0.72) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Lyra Therapeutics’ earnings, with estimates ranging from ($0.78) to ($0.65). Lyra Therapeutics posted earnings of ($0.49) per share during the same quarter last year, which indicates a negative year over year growth rate of 46.9%. The firm is expected to report its next earnings report on Tuesday, November 9th.
On average, analysts expect that Lyra Therapeutics will report full year earnings of ($2.79) per share for the current year, with EPS estimates ranging from ($3.17) to ($2.57). For the next year, analysts expect that the company will post earnings of ($2.69) per share, with EPS estimates ranging from ($3.56) to ($2.08). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Lyra Therapeutics.
Lyra Therapeutics (NASDAQ:LYRA) last released its quarterly earnings results on Monday, August 9th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.24).
NASDAQ LYRA traded up $0.14 on Friday, hitting $8.77. 4 shares of the stock were exchanged, compared to its average volume of 114,856. The company has a market capitalization of $114.02 million, a PE ratio of -3.65 and a beta of 1.69. The business’s fifty day moving average is $7.25 and its 200 day moving average is $9.11. Lyra Therapeutics has a 52 week low of $5.83 and a 52 week high of $16.50.
Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Lyra Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 220,029 shares of the company’s stock worth $1,767,000 after purchasing an additional 8,143 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Lyra Therapeutics during the second quarter valued at approximately $93,000. Nuveen Asset Management LLC purchased a new stake in shares of Lyra Therapeutics during the first quarter valued at approximately $208,000. Walleye Capital LLC bought a new position in shares of Lyra Therapeutics during the second quarter valued at approximately $153,000. Finally, Citadel Advisors LLC bought a new position in shares of Lyra Therapeutics during the second quarter valued at approximately $156,000. 53.70% of the stock is currently owned by institutional investors.
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Read More: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.